Aimmune Therapeutics, Inc. announced that Nestlé Health Science will make a $145.0 million equity investment in the company. Aimmune and Nestlé Health Science also entered into a strategic collaboration agreement designed to enable the successful development and commercialization of innovative food allergy therapies. The company also announced that Nestlé Health Science CEO Greg Behar Will Join the company's Board of Directors.